Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Non-requirement of Reporter Element to Drive Label-free Technology Market - Label-free detection and biomolecular interaction analysis technology, as the name suggests, requires no labels or reporter elements
Non-requirement of Reporter Element to Drive Label-free Technology Market

 

PRZOOM - /newswire/ - Mountain View, CA, United States, 2008/12/01 - Label-free detection and biomolecular interaction analysis technology, as the name suggests, requires no labels or reporter elements.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

This direct detection has many advantages over traditional detection technologies, the chief among them the screening of protein-protein interactions, which are otherwise a major challenge.

New analysis from Frost & Sullivan (technicalinsights.frost.com), Advances in Label-free Detection Technologies, finds that large pharmaceutical and biotech companies are showing increasing interest in the technology.

If you are interested in an analysis, which provides manufacturers, end users, and other industry participants with an overview, summary, challenges, and latest coverage of advances in optical networks, then send an email to Mireya Castilla, Corporate Communications, at mireya.castilla[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by email.

Many problems are overcome just by the absence of labels, as they tend to alter the molecules under study, which in turn affects the binding or physicochemical properties. With label-free detection, there is lower interference from compound autofluorescence and color quenching, leading to fewer false positives and negatives. It also does away with the problems cropping up from the secondary detection of auxiliary reagents.

Label-free assays enable the use of natural ligands and substrates, something the label-based assays are unable to support. Besides, label-free technologies help avoid the use of radioactive labels, thereby enhancing lab safety and contributing to cost savings, as there are no radioactive waste disposal costs.

Currently, lack of robust, quality assays for target screening and validation leads to a high 25 percent of targets being ignored. However, label-free technology offers an option to screen the high proportion of orphaned targets, mostly protein-protein interactions. This can be used as a selling point, especially to those pharmaceutical and biotech companies that investigate orphaned targets.

For all its inherent advantages, the high costs of label-free technology can be a restraint to its adoption. Not only are the instruments costly, being priced above $200,000, the cost of the consumables is also high. The fact that the technology is fairly new could also act as a deterrent.

"Probably one of the biggest restraining factors inhibiting the widespread adoption of label-free detection and screening is the overbearing cost of the equipment, which requires capital investment," notes Frost & Sullivan Technical Insights Research Analyst Rasika Ramachandran. "This is compounded by the fact that it is still a budding technology for which the drug discovery customers might not be willing to pay the big buck."

The consumables include Society for Biomolecular Sciences (SBS)-standard microtiter plates embedded with sensors in every well. The sensors are expensive and make this technology costly, especially for academics and specialty pharmaceutical companies that depend on private and venture funding. Larger pharmaceutical and biotech companies with good funding might, however, be able to afford this technology.

"As this is a nascent technology, label-free technology providers can form partnerships with small biotech firms, whereby the technology can be provided at a discounted rate," notes Ramachandran. "The biotech will benefit from the use of a robust new technology, while the label-free company, in addition to the revenues that such a partnership will bring, can use the results obtained through field studies to fine-tune its technology."

Advances in Label-free Detection Technologies, a part of the Technical Insights subscription, provides a technology overview and outlook for the analysis of the label-free technology industry for biomolecular interaction analysis, from a technological and application perspective. Further, this research service includes detailed technology analysis and industry trends evaluated following extensive interviews with market participants. Interviews with the press are available.

Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters, and research services.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership™ empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

Advances in Label-free Detection Technologies - D12D-55

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Non-requirement of Reporter Element to Drive Label-free Technology Market

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan |
Contact: Mireya Castilla 
210.247.3830 mireya.castilla[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  Triggr & Bloom

Visit  NAKIVO, Inc.

Visit  JobsWare.com







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today